- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.05. | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results | 154 | GlobeNewswire (Europe) | Updated Phase 2 data to be presented at ASCO for vilastobart, a tumor-activated, Fc-enhanced, anti-CTLA-4, in combination with atezolizumab in patients with metastatic microsatellite stable colorectal... ► Artikel lesen | |
| 08.05. | Xilio Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 02.05. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 116 | GlobeNewswire (Europe) | WALTHAM, Mass., May 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 23.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ... | 2 | GlobeNewswire (USA) | ||
| 08.04. | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.04. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 118 | GlobeNewswire (Europe) | WALTHAM, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 11.03. | Xilio Therapeutics reports Q4 results | 2 | Seeking Alpha | ||
| 11.03. | Xilio Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 11.03. | Xilio Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 11.03. | Xilio advances cancer treatments, secures AbbVie collaboration | 7 | Investing.com | ||
| 11.03. | Xilio Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.03. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results | 154 | GlobeNewswire (Europe) | Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated in the middle of 2025 Advancing masked T... ► Artikel lesen | |
| 14.02. | AbbVie and Xilio announce immunotherapy partnership worth over $2.1bn | 10 | PMLiVE | ||
| 13.02. | AbbVie and Xilio to collaborate on antibody-based immunotherapies | 6 | Pharmaceutical Technology | ||
| 12.02. | Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? | 3 | Benzinga.com | ||
| 12.02. | AbbVie signs heavily backloaded $2.1B Xilio biobucks pact in Big Pharma's latest T-cell engager deal | 12 | FierceBiotech | ||
| 12.02. | AbbVie, Xilio Hook up | 4 | Baystreet.ca | ||
| 12.02. | AbbVie and Xilio Therapeutics announce collaboration and option agreement | 7 | Seeking Alpha | ||
| 12.02. | AbbVie, Xilio Partner To Develop Novel Tumor-Activated Immunotherapies; Stock Up In Pre-market | 11 | RTTNews |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,089 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
| BIOXXMED | 0,434 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
| VIVOSIM LABS | 1,640 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
| OCUGEN | 0,788 | +5,57 % | Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease | MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
| BIO-GATE | 1,050 | -3,67 % | Bio-Gate: Zusätzlicher Wachstumstreiber bei Wundversorgung | Nach Darstellung der Analysten Matthias Greiffenberger und Cosmin Filker von GBC besitzt die Bio-Gate AG für ein Spray im Bereich der Wundversorgung zusätzliche Vermarktungsoptionen mit großem Potenzial.... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,588 | +5,00 % | Defence Therapeutics Inc.: Defence Therapeutics to Attend Bio International Convention in Boston, June 2025 | Montreal, Quebec--(Newsfile Corp. - May 28, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing advanced... ► Artikel lesen | |
| VAXART | 0,392 | -3,07 % | Vaxart seeks shareholder nod for reverse stock split | ||
| BURCON NUTRASCIENCE | 0,068 | +4,59 % | Burcon NutraScience Corporation: Burcon to Participate in 2025 Canadian Climate Investor Conference | Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,242 | +6,14 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update | Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate... ► Artikel lesen | |
| AFFIMED | 0,530 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market | OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. ("AIM" or the "Company") (OTC Pink: AIMI) - an immuno-pharma company focused on the research and development of therapeutics to... ► Artikel lesen | |
| IMMUNIC | 0,584 | +2,46 % | Immunic sammelt 65 Millionen Dollar ein - Aktie reagiert | Immunic meldet für die erste Tranche einer Kapitalmaßnahme einen Bruttoerlös von rund 65 Millionen Dollar. Das Biotech-Unternehmen platzierte im Rahmen eines öffentlichen Angebots vorfinanzierte Aktien-Warrants... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,106 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen | |
| CEL-SCI | 2,370 | 0,00 % | Pre-market Movers: Navitas Semiconductor, Longevity Health, CEL-SCI, Hyperscale Data, Sunrun | PHILADELPHIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 06.35 A.M. ET).In the Green Navitas Semiconductor Corporation (NVTS) is... ► Artikel lesen |
Das Unternehmen XILIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,966 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.